Dr. Chantal Bader
Über
Chantal Bader studierte Pharmazie an der Ruprecht-Karls-Universität Heidelberg, Deutschland (Approbation als Apothekerin, 2016). Nach ihrem Studium fertigte sie ihre Masterarbeit und 2016 die anschließende Promotion in der Abteilung von Rolf Müller am HIPS an, wo sie an der Isolierung und Charakterisierung verschiedener Naturstoffe aus Myxobakterien arbeitete. Unterstützt durch das DFG Walter-Benjamin-Stipendium wechselte sie an das Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (Florida, USA), wo sie 2022 der Gruppe von Prof. Shen beitrat. Als Leiterin funktionsorientierter Screenings der dort ansässigen umfangreichen Extraktbibliothek erweiterte sie ihren Schwerpunkt auf die Entdeckung von Anti-Gram-negativen Antibiotika und Antiplasmodika aus Actinobakterien. Im Juli 2024 kehrte Chantal im Rahmen des Young AcademiXX-Programmes ans HIPS zurück.
2024
Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism
Garcia R, Popoff A, Bader C, Löhr J, Walesch S, Walt C, Boldt J, Bunk B, Haeckl F, Gunesch A, …, Bach T, Müller R (2024)
Chem 10: 1-20DOI: 10.1016/j.chempr.2024.04.019
Elucidation of unusual biosynthesis and DnaN-targeting mode of action of potent anti-tuberculosis antibiotics Mycoplanecins
Fu C, Liu Y, Walt C, Rasheed S, Bader C, Lukat P, Neuber M, Haeckl F, Blankenfeldt W, Kalinina O, Müller R (2024)
Nat Commun 15 (1)DOI: 10.1038/s41467-024-44953-5
2023
Genome-Guided Discovery of the Myxobacterial Thiolactone-Containing Sorangibactins
Gao Y, Walt C, Bader C, Müller R (2023)
ACS chemical biology 18 (4): 924-932DOI: 10.1021/acschembio.3c00063
2022
Darobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering
Seyfert C, Porten C, Yuan B, Deckarm S, Panter F, Bader C, Coetzee J, Deschner F, Tehrani K, Higgins P, …, Herrmann J, Müller R (2022)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202214094
Large-Scale Interlaboratory DI-FT-ICR MS Comparability Study Employing Various Systems
Forcisi S, Moritz F, Thompson C, Kanawati B, Uhl J, Afonso C, Bader C, Barsch A, Boughton B, Chu R, …, Laukien F, Schmitt-Kopplin P (2022)
Journal of the American Society for Mass SpectrometryDOI: 10.1021/jasms.2c00082
Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA
Fathalla R, Fröhner W, Bader C, Fischer P, Dahlem C, Chatterjee D, Mathea S, Kiemer A, Arthanari H, Müller R, …, Ducho C, Engel M (2022)
Journal of medicinal chemistryDOI: 10.1021/acs.jmedchem.2c01275
Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors
Haack P, Harmrolfs K, Bader C, Garcia R, Gunesch A, Haid S, Popoff A, Voltz A, Kim H, Bartenschlager R, Pietschmann T, Müller R (2022)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202212946
Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium
Bader C, Panter F, Garcia R, Tchesnokov E, Haid S, Walt C, Spröer C, Kiefer A, Götte M, Overmann J, Pietschmann T, Müller R (2022)
Chem. Eur. J. 28 (10)DOI: 10.1002/chem.202104484
2021
Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering
Groß S, Panter F, Pogorevc D, Seyfert C, Deckarm S, Bader C, Herrmann J, Müller R (2021)
Chem. Sci. 12 (35): 11882-11893DOI: 10.1039/d1sc02725e
Sesbanimide R, a Novel Cytotoxic Polyketide Produced by Magnetotactic Bacteria
Awal R, Haack P, Bader C, Riese C, Schüler D, Müller R (2021)
mBio 12 (3)DOI: 10.1128/mBio.00591-21
Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity
Ropponen H, Bader C, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch A (2021)
ChemMedChem 16 (13): 2089-2093DOI: 10.1002/cmdc.202100067
Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics
Panter F, Bader C, Müller R (2021)
Chem. Sci. 12 (17): 5994-6010DOI: 10.1039/d0sc06919a
The Sandarazols are Cryptic and Structurally Unique Plasmid-Encoded Toxins from a Rare Myxobacterium*
Panter F, Bader C, Müller R (2021)
Angewandte Chemie (International ed. in English) 60 (15): 8081-8088DOI: 10.1002/anie.202014671
Expanding the Scope of Detectable Microbial Natural Products by Complementary Analytical Methods and Cultivation Systems
Bader C, Haack P, Panter F, Krug D, Müller R (2021)
Journal of natural products 84 (2): 268-277DOI: 10.1021/acs.jnatprod.0c00942
2020
Supercritical Fluid Extraction Enhances Discovery of Secondary Metabolites from Myxobacteria
Bader C, Neuber M, Panter F, Krug D, Müller R (2020)
Analytical chemistry 92 (23): 15403-15411DOI: 10.1021/acs.analchem.0c02995
In depth natural product discovery - Myxobacterial strains that provided multiple secondary metabolites
Bader C, Panter F, Müller R (2020)
Biotechnol Adv 39DOI: 10.1016/j.biotechadv.2019.107480
2019
Synthesis of New Cyclomarin Derivatives and Their Biological Evaluation towards Mycobacterium Tuberculosis and Plasmodium Falciparum
Kiefer A, Bader C, Held J, Esser A, Rybniker J, Empting M, Müller R, Kazmaier U (2019)
Chem. Eur. J. 25 (37): 8894-8902DOI: 10.1002/chem.201901640
Engineering Atypical Tetracycline Formation in Amycolatopsis sulphurea for the Production of Modified Chelocardin Antibiotics
Lukežic T, Fayad A, Bader C, Harmrolfs K, Bartuli J, Groß S, Lešnik U, Hennessen F, Herrmann J, Pikl Š, Petkovic H, Müller R (2019)
ACS Chem. Biol. 14 (3): 468-477DOI: 10.1021/acschembio.8b01125
2018
Concepts and Methods to Access Novel Antibiotics from Actinomycetes
Hug J, Bader C, Remškar M, Cirnski K, Müller R (2018)
Antibiotics 7 (2)DOI: 10.3390/antibiotics7020044